ArticleFuture oncology (London, England)2024

Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs.

Jiling Niu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.